The role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Ημερομηνία
2020Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Gliomas are the most common primary brain tumors in adults. They are generally very resistant to treatment and are therefore associated with negative outcomes. MicroRNAs (miRNAs) are small, non-coding RNA molecules that affect many cellular processes by regulating gene expression and, post-transcriptionally, the translation of mRNAs. MiRNA-21 has been consistently shown to be upregulated in glioma and research has shown that it is involved in a wide variety of biological pathways, promoting tumor cell survival and invasiveness. Furthermore, it has been implicated in resistance to treatment, both against chemotherapy and radiotherapy. In this review, we gathered the existent data on miRNA-21 and gliomas, in terms of its expression levels, association with grade and prognosis, the pathways it involves and its targets in glioma, and finally how it leads to treatment resistance. Furthermore, we discuss how this knowledge could be applied in clinical practice in the years to come. To our knowledge, this is the first review to assess in extent and depth the role of miRNA-21 in gliomas. © 2020
Collections
Related items
Showing items related by title, author, creator and subject.
-
Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with mdscs and tregs in HER2-negative metastatic breast cancer patients
Papadaki M.A., Aggouraki D., Vetsika E.-K., Xenidis N., Kallergi G., Kotsakis A., Georgoulias V. (2021)Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood ... -
Primary Gross Tumor Volume (pGTV) and Tumor Response in Locally Advanced Rectal Cancer (LARC). Is There Any Correlation?
Tsoukalas N., Mosa E., Tsapakidis K., Kamposioras K., Tolia M. (2021)[No abstract available] -
Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?
Sereti E., Karagianellou T., Kotsoni I., Magouliotis D., Kamposioras K., Ulukaya E., Sakellaridis N., Zacharoulis D., Dimas K. (2018)The prognosis of pancreatic ductal adenocarcinoma (PDAC), the eighth most lethal cancer for men and ninth for women worldwide, remains dismal. The increasing rates of deaths by PDAC indicate that the overall management of ...

